These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31986437)

  • 1. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
    Lamarca A; Edeline J; McNamara MG; Hubner RA; Nagino M; Bridgewater J; Primrose J; Valle JW
    Cancer Treat Rev; 2020 Mar; 84():101936. PubMed ID: 31986437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
    Edeline J; Hirano S; Bertaut A; Konishi M; Benabdelghani M; Uesaka K; Watelet J; Ohtsuka M; Hammel P; Kaneoka Y; Joly JP; Yamamoto M; Monard L; Ambo Y; Louvet C; Ando M; Malka D; Nagino M; Phelip JM; Ebata T
    Eur J Cancer; 2022 Mar; 164():80-87. PubMed ID: 35182925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
    Primrose JN; Fox RP; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans JTR; Stocken D; Praseedom R; Ma YT; Davidson B; Neoptolemos JP; Iveson T; Raftery J; Zhu S; Cunningham D; Garden OJ; Stubbs C; Valle JW; Bridgewater J;
    Lancet Oncol; 2019 May; 20(5):663-673. PubMed ID: 30922733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
    Akhoundova Sanoyan D; McNamara MG; Lamarca A; Valle JW
    Curr Opin Oncol; 2020 Jul; 32(4):364-369. PubMed ID: 32541326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adjuvant treatment of biliary tract cancers: Who and how?].
    Edeline J
    Bull Cancer; 2020 Jan; 107(1):48-53. PubMed ID: 31980143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
    Rizzo A; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
    [No Abstract]   [Full Text] [Related]  

  • 11. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
    Shroff RT; Kennedy EB; Bachini M; Bekaii-Saab T; Crane C; Edeline J; El-Khoueiry A; Feng M; Katz MHG; Primrose J; Soares HP; Valle J; Maithel SK
    J Clin Oncol; 2019 Apr; 37(12):1015-1027. PubMed ID: 30856044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landmark Series: Gallbladder Cancer.
    Gamboa AC; Maithel SK
    Ann Surg Oncol; 2020 Aug; 27(8):2846-2858. PubMed ID: 32474816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.
    Bridgewater J; Fletcher P; Palmer DH; Malik HZ; Prasad R; Mirza D; Anthony A; Corrie P; Falk S; Finch-Jones M; Wasan H; Ross P; Wall L; Wadsley J; Evans TR; Stocken D; Stubbs C; Praseedom R; Ma YT; Davidson B; Neoptolemos J; Iveson T; Cunningham D; Garden OJ; Valle JW; Primrose J;
    J Clin Oncol; 2022 Jun; 40(18):2048-2057. PubMed ID: 35316080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
    Kish M; Chan K; Perry K; Ko YJ
    Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
    Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
    BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
    Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM
    J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
    McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
    J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.